Eiger’s lead clinical programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3. Eiger has filed an NDA and MAA for lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies. FDA PDUFA date is November 20, 2020.
Time is critical to patients with rare diseases. Eiger strives to quickly develop important therapies as safely and effectively as possible, shortening treatment development times and expediting delivery of life-changing therapies to patients.
We are focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases.
We are committed to more rapidly delivering important medicines to patients in need through developing well-characterized drugs acting on newly identified or novel targets.
Eiger has discovered untapped therapeutic potential of molecules with well understood safety profiles with the goal of developing medications for life-threatening diseases that have no approved treatments.